Company
Bioelectronics
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
8
510(k), De Novo and PMA
Device trials
18
As lead sponsor, any status
Adverse event reports
1
Received Nov 1, 2025 to Nov 19, 2026
Recall records
1
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$50K
1 Form D offering, 2012 to 2012
Equity
$50K
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: equity, $50K raised, filed Nov 9, 2012, 1 investor.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Filed Nov 9, 2012 | Equity | $50K | Open-ended | 1 | 04.3 | Form D ↗Nov 9, 2012 |
Company details
From the company's latest Form D.
- Legal name
- BioElectronics Corp
- Headquarters
- Frederick, Maryland
- Incorporated
- Maryland over five years before filing
- Entity type
- Corporation
- Revenue range
- $1 - $1,000,000
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1320869 ↗
Executives, directors and promoters
As listed on the latest Form D.
- Rick StaelinDirector, Chairman of the Board
- Mary WhelanDirector
- Andrew WhelanExecutive Officer, Director
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
- NerivioInfinity510(k)
K232152 · Decided Nov 8, 2023 · 112 days after receipt
Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT) · Neurology & Neurosurgery
- Nerivio510(k)
K223169 · Decided Feb 6, 2023 · 118 days after receipt
Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT) · Neurology & Neurosurgery
- Nerivio, FGD000075-4.7510(k)
K203181 · Decided Jan 22, 2021 · 88 days after receipt
Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT) · Neurology & Neurosurgery
- ActiPatch510(k)
K192234 · Decided Jan 31, 2020 · 165 days after receipt
Device type: Nonthermal Shortwave Therapy Device Indicated For Over The Counter Use For The Treatment Of Pain (PQY) · Physical Medicine & Rehabilitation
- RecoveryRx510(k)
K190251 · Decided Jun 28, 2019 · 141 days after receipt
Device type: Diathermy, Shortwave, For Use Other Than Applying Therapeutic Deep Heat (ILX) · Physical Medicine & Rehabilitation
- Nerivio MigraNew device typeDe Novo
DEN180059 · Decided May 20, 2019 · 195 days after receipt
Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT) · Neurology & Neurosurgery
- ActiPatch(R)510(k)
K152432 · Decided Feb 3, 2017 · 526 days after receipt
Device type: Nonthermal Shortwave Therapy Device Indicated For Over The Counter Use For The Treatment Of Pain (PQY) · Physical Medicine & Rehabilitation
- CUR Model 1510(k)
K160052 · Decided May 20, 2016 · 130 days after receipt
Device type: Stimulator, Nerve, Transcutaneous, Over-The-Counter (NUH) · Neurology & Neurosurgery
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- MINDZ-- Minimally Invasive Approach Pilot StudyNot yet recruiting
NCT07543406 · 5 participants (planned) · Start Oct 1, 2026 · Primary completion Sep 1, 2027
Device: MINDZ Subdural Electrode Grid · For: Intraoperative Neurophysiological Monitoring
Sites: Zurich, Switzerland
- A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant MigrainePivotal-lookingRecruiting
NCT07719608 · 150 participants (planned) · Start Dec 1, 2026 · Primary completion Oct 1, 2028
Device: Neurostimulator · For: Resistant Migraine; Chronic Migraine Headache; Headache (Migraine) and 1 more
Sites: Newnan, Georgia; Olney, Maryland; Charlotte, North Carolina
- The RECLAIM Study.Pivotal-lookingRecruiting
NCT06450444 · 110 participants (planned) · Start Jun 24, 2024 · Primary completion Apr 1, 2027
Device: PRIMUS · For: Chronic Migraine; High Frequency Episodic Migraine
Sites: Broadmeadow, Australia; Buderim, Australia; Wilrijk, Belgium · 11 sites in all
NCT07113470 · 10 participants (planned) · Start Apr 13, 2026 · Primary completion May 31, 2027
Device: The Salvia PRIMUS implantable neurostimulator System · For: Chronic Cluster Headache
Sites: Leiden, Netherlands
- First Evaluation of a Craniofacial Nerve Stimulation System in Chronic MigraineActive, not recruiting
NCT05858801 · 7 participants · Start May 9, 2023 · Primary completion Dec 9, 2023
Device: PRIMUS · For: Chronic Migraine
Sites: Roeselare, Belgium
- REsponse to Combined SONS and ONS in Chronic Cluster headachEActive, not recruiting
NCT05868044 · 5 participants (planned) · Start May 2, 2023 · Primary completion Apr 23, 2024
Device: PRIMUS · For: Chronic Cluster Headache
Sites: Buderim, Australia
Reports received
1
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
1
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 1 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Nerivio Infinity. Model/Catalog Number: FGD000100. Software Version: FW Version 4.1.2.0, App version 7.28.0.11Open, Classified
Z-2855-2026 · Started Mar 23, 2026 · Posted by FDA Jul 31, 2026
Reason given: Potential for the batter to have a thermal-runway event during charging, resulting in smoke and odor.
Cause as FDA categorized it: Component design/selection · Device type: Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine (QGT)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.